SOLICITATION NOTICE
A -- ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS
- Notice Date
- 4/12/2021 7:43:07 AM
- Notice Type
- Presolicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- BAA-DAIT-75N93021R00008
- Response Due
- 4/27/2021 12:00:00 PM
- Archive Date
- 05/12/2021
- Point of Contact
- Emily Bannister, Phone: 2406695135, Tom Bahrami, Phone: 2406695147
- E-Mail Address
-
emily.bannister@nih.gov, bahramit@niaid.nih.gov
(emily.bannister@nih.gov, bahramit@niaid.nih.gov)
- Description
- Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes�of Health (NIH), of the Department of Health and Human Services (DHHS) supports�research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the�prevention, treatment, and diagnosis of infectious and immune-mediated diseases.�NIAID�s Division of Allergy, Immunology and Transplantation (DAIT), Division of AIDS�(DAIDS), and Division of Microbiology and Infectious Diseases (DMID) have an�interest in supporting side-by-side comparisons of adjuvants, to include�comprehensive assessments of the strength, quality, breadth, and durability of�immune responses. Description The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to�establish immunological profiles of adjuvants that work through different�mechanisms, facilitating the identification of the most promising adjuvant:Mtb�immunogen candidates for clinical development and potential immune correlates of�protection. The range of adjuvants to be evaluated may include novel classes of�adjuvants being developed for other infections and immune-oncology therapeutics,�as well as adjuvants already being developed for TB vaccines.�It is anticipated that one cost reimbursement, completion type contract will be�awarded for a five [5]-year period of performance beginning on or about 7/22/22. NIAID anticipates that the average annual total cost (direct and indirect costs�combined) is $4 million per contract. However, it is anticipated that the total cost for�the award(s) may vary depending upon the scope of the project and the technical�objectives of the award(s). The length of time for which funding is requested should�be consistent with the nature and complexity of the proposed research. In no event�shall the period of performance proposed by an offeror exceed five [5] years.�Any responsible offeror may submit a proposal which shall be considered by the�Agency. This BAA will be available electronically on/about April, 28, 2021, and may�be accessed through SAM.gov https://beta.sam.gov/. This notice does not commit�the Government to award a contract. No collect calls will be accepted. No facsimile�transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the�NIAID electronic Contract Proposal Submission (eCPS) website.�For directions on using eCPS, go to the website https://ecps.nih.gov/ and then click�on ""How to Submit.""
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/0ae8b5c69be3459aa07512268dbb953b/view)
- Record
- SN05968948-F 20210414/210412230113 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |